Oftidor (Dorzolamide Hydrochloride)

Dorzolamide hydrochloride, the active ingredient in Oftidor, is a carbonic anhydrase inhibitor presented as a ophthalmic solution for topical eye use. It helps lower intra‑ocular pressure in patients with certain types of glaucoma and ocular hypertension.

GNH USA supplies Oftidor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oftidor is a carbonic anhydrase inhibitor used in the management of ocular conditions that affect intra‑ocular pressure. - Primary open‑angle glaucoma: reduces the risk of optic nerve damage by lowering intra‑ocular pressure. - Ocular hypertension: helps maintain pressure within normal limits to prevent progression to glaucoma. - Secondary glaucoma (e.g., steroid‑induced): assists in controlling pressure when steroids elevate intra‑ocular pressure.

Side effects are generally mild and related to local eye irritation.

Common Side Effects: - Burning or stinging sensation upon instillation. - Transient blurred vision. - Foreign‑body sensation. - Conjunctival hyperemia (red eye). - Mild ocular discomfort.

Serious or Rare Side Effects: - Persistent ocular inflammation. - Corneal edema or ulceration. - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Vision loss unrelated to glaucoma progression.

When using Oftidor, consider the following precautions to ensure safe and effective therapy. - Monitor intra‑ocular pressure: regular eye‑pressure checks are essential. - Assess for sulfonamide allergy: dorzolamide contains a sulfonamide moiety. - Avoid concurrent use with other carbonic anhydrase inhibitors unless directed. - Caution in patients with severe renal impairment: systemic absorption may be increased. - Store at room temperature: keep in the original container, protect from light and moisture.

Oftidor may interact with other ophthalmic or systemic medications. Review the following interaction categories.

Major Interactions (Avoid): - Concurrent use with other topical carbonic anhydrase inhibitors (e.g., brinzine). May cause excessive pressure reduction. - Systemic carbonic anhydrase inhibitors (acetazolamide): additive intra‑ocular pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Topical beta‑blockers (timolol, betaxolol): combined effect on pressure may require dose adjustment. - Non‑steroidal anti‑inflammatory eye drops: may increase risk of ocular irritation. - Anticholinergic agents: potential for reduced tear production, worsening dry‑eye symptoms.